Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: Intermediate Prophylactic vs Therapeutic Dose Anticoagulation in COVID-19
NCT04406389Phase 4Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2020
- Primary completion
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 4 trial of enoxaparin, heparin, fondaparinux, argatroban in coronavirus disease 2019 (COVID-19), sponsored by Weill Cornell Medicine. Started Oct 2020; status: terminated.
02
Drugs
enoxaparinheparinfondaparinuxargatroban
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04406389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04406389.